Latest Ebola Outbreak: Global Health Emergency in Congo & Uganda

Here is your publish-ready WordPress Gutenberg block article based on verified primary sources:

The World Health Organization (WHO) declared the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, marking the first such declaration for this strain since its discovery. The outbreak, driven by the Bundibugyo virus (BVD)—a rare and less-studied variant of Ebola—has now infected over 300 people and killed at least 88, with cases confirmed in both countries. Unlike the more common Ebola virus (Zaire ebolavirus), BVD lacks approved vaccines or therapeutics, complicating response efforts.

Key details from WHO and verified reporting:

• Geographic spread: The DRC accounts for all but two of the confirmed cases, both reported in neighboring Uganda. The outbreak originated in Ituri province, near borders with Uganda and South Sudan.
• Strain specifics: This is only the third recorded outbreak of BVD since its identification in 2007. The virus has a mortality rate ranging from 25% to 80%, depending on access to care.
• Surveillance gaps: Health officials warn the true scale may be larger due to limited testing capacity and underreporting in remote areas.
• International risk: While WHO emphasized this does not meet pandemic criteria, neighboring countries remain at high risk of transmission.

The declaration follows weeks of escalating cases, with Uganda reporting its first BVD infections on May 16, 2026. The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, stated in a May 17 social media post that neighboring countries are at high risk of further spread, urging accelerated vaccine research and cross-border coordination.

Unlike the Zaire ebolavirus—against which an FDA-approved vaccine exists—BVD presents unique challenges. The CDC notes that Bundibugyo virus disease typically begins with dry symptoms (fever, fatigue, muscle pain) progressing to wet symptoms (vomiting, diarrhea, internal bleeding) in later stages. Treatment remains supportive, with experimental drugs like INMAZEB (atoltivimab/maftivimab/odesivimab) showing promise against Zaire ebolavirus but untested for BVD.

Public health experts highlight three critical factors in the current crisis:

1. Diagnostic delays: BVD’s symptoms overlap with malaria and typhoid, leading to misdiagnosis in regions with weak healthcare infrastructure.

2. Vaccine development: While a Zaire ebolavirus vaccine exists, no BVD-specific vaccine has undergone clinical trials. WHO is prioritizing adaptive research.

3. Cross-border coordination: Uganda’s cases underscore the need for rapid response protocols between DRC, Uganda and South Sudan.

U.S. Citizens in the DRC have been identified as potentially exposed, though no infections have been reported among them. The CDC advises travelers to avoid nonessential trips to affected regions and emphasizes strict infection control measures for healthcare workers.

Looking ahead, WHO’s emergency committee will monitor the outbreak’s trajectory, with particular attention to:

• Expansion of laboratory testing to confirm cases and track transmission chains.
• Deployment of experimental therapies (e.g., INMAZEB) under compassionate-use protocols.
• Strengthening surveillance in high-risk border areas.

For the public, the WHO reiterates that Ebola spreads through direct contact with body fluids of infected individuals or contaminated materials. Preventive measures include hand hygiene, avoiding bushmeat consumption, and reporting fever symptoms promptly to health authorities.

Note: This article is based on verified WHO declarations, CDC guidance, and peer-reviewed Ebola literature. For real-time updates, consult the WHO or CDC.